Selected clinical trials in advanced-stage Hodgkin lymphoma without the use of novel agents
| Trial . | N . | Clinical disease features . | Median age, y . | Therapy received/arms of treatment . | Median follow-up, y . | Response . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| Stanford V49 | 142 | Stage III or IV or locally extensive mediastinal stage I or II | 28 | Stanford V: vinblastine, doxorubicin, vincristine, bleomycin, etoposide, and prednisone followed by 36 to 44 Gy RT | 5.4 | 5-year freedom from progression 89% | 5-year OS 96% | |
| S081625 | 331 | Stage III or IV | 31 | ABVD × 2 → PET 1. If CR, then ABVD × 4 2. If not in CR, then switch to escBEACOPP × 6 | 5.9 | PET2– 82% | 5-year PFS Overall 74% PET2– 76% PET2 + 66% | 5-year OS Overall 94% PET2– 96% PET2 + 86% |
| RATHL24 | 1214 | Stage IIB to IV or stage IIA with adverse features | 33 | ABVD × 2 → PET 1. If PET–, then AVD × 4 2. If PET+, then switch to escBEACOPP | 3.4 | PET– 83.7% | 3-year PFS PET2– 85.7% PET2 + 67.5% | 3-year OS PET2– 97.2% PET2 + 87.8% |
| HD1827 | 2101 | Stage III or IV, stage II with B symptoms or bulky | 32 | escBEACOPP × 2 → PET If PET–, then 1. escBEACOPP × 6 (later amended to escBEACOPP × 4) or 2. escBEACOPP × 2 If PET+, then 3. escBEACOPP × 6 | 5.5 | Overall 5-year PFS 89.4% PET– Overall 5-year PFS 91.4% escBEACOPP × 8 (or × 6) 5-year PFS 90.8% escBEACOPP × 4 5-year PFS 92.2% PET+ 5-year PFS 88.3% | Overall 5-year OS 95.6% PET– Overall 5-year OS 96.3% escBEACOPP × 8 (or × 6) 5-year OS 95.4% escBEACOPP × 4 5-year OS 97.7% PET+ 5-year OS 95.5% | |
| AHL201128 | 826 | Stage III or IV, high-risk IIB | 30 | escBEACOPP × 2 → PET (2) Standard group: 1. escBEACOPP × 2 → PET (4) If PET–, then escBEACOPP × 2 If PET+, then salvage or PET-adapted approach: 2. If PET+, then escBEACOPP × 2 → PET (4) If PET–, then escBEACOPP × 2 If PET+, then salvage or 3. If PET–, then ABVD × 2 → PET (4) If PET–, then ABVD × 2 If PET+, then salvage | 4.2 | Overall standard arm: 5-year PFS 86.2% PET-adapted arm: 5-year PFS 85.7% PET2 and PET4– 5-year PFS 92.5% PET2+ and PET 4– 5-year PFS 75.4% PET 4+ 5-year PFS 46.5% | Overall Standard Arm: 5-year OS 95.2% PET-adapted arm: 5-year OS 96.4% |
| Trial . | N . | Clinical disease features . | Median age, y . | Therapy received/arms of treatment . | Median follow-up, y . | Response . | PFS . | OS . |
|---|---|---|---|---|---|---|---|---|
| Stanford V49 | 142 | Stage III or IV or locally extensive mediastinal stage I or II | 28 | Stanford V: vinblastine, doxorubicin, vincristine, bleomycin, etoposide, and prednisone followed by 36 to 44 Gy RT | 5.4 | 5-year freedom from progression 89% | 5-year OS 96% | |
| S081625 | 331 | Stage III or IV | 31 | ABVD × 2 → PET 1. If CR, then ABVD × 4 2. If not in CR, then switch to escBEACOPP × 6 | 5.9 | PET2– 82% | 5-year PFS Overall 74% PET2– 76% PET2 + 66% | 5-year OS Overall 94% PET2– 96% PET2 + 86% |
| RATHL24 | 1214 | Stage IIB to IV or stage IIA with adverse features | 33 | ABVD × 2 → PET 1. If PET–, then AVD × 4 2. If PET+, then switch to escBEACOPP | 3.4 | PET– 83.7% | 3-year PFS PET2– 85.7% PET2 + 67.5% | 3-year OS PET2– 97.2% PET2 + 87.8% |
| HD1827 | 2101 | Stage III or IV, stage II with B symptoms or bulky | 32 | escBEACOPP × 2 → PET If PET–, then 1. escBEACOPP × 6 (later amended to escBEACOPP × 4) or 2. escBEACOPP × 2 If PET+, then 3. escBEACOPP × 6 | 5.5 | Overall 5-year PFS 89.4% PET– Overall 5-year PFS 91.4% escBEACOPP × 8 (or × 6) 5-year PFS 90.8% escBEACOPP × 4 5-year PFS 92.2% PET+ 5-year PFS 88.3% | Overall 5-year OS 95.6% PET– Overall 5-year OS 96.3% escBEACOPP × 8 (or × 6) 5-year OS 95.4% escBEACOPP × 4 5-year OS 97.7% PET+ 5-year OS 95.5% | |
| AHL201128 | 826 | Stage III or IV, high-risk IIB | 30 | escBEACOPP × 2 → PET (2) Standard group: 1. escBEACOPP × 2 → PET (4) If PET–, then escBEACOPP × 2 If PET+, then salvage or PET-adapted approach: 2. If PET+, then escBEACOPP × 2 → PET (4) If PET–, then escBEACOPP × 2 If PET+, then salvage or 3. If PET–, then ABVD × 2 → PET (4) If PET–, then ABVD × 2 If PET+, then salvage | 4.2 | Overall standard arm: 5-year PFS 86.2% PET-adapted arm: 5-year PFS 85.7% PET2 and PET4– 5-year PFS 92.5% PET2+ and PET 4– 5-year PFS 75.4% PET 4+ 5-year PFS 46.5% | Overall Standard Arm: 5-year OS 95.2% PET-adapted arm: 5-year OS 96.4% |
RT, radiotherapy.